Should I buy or sell Eiger BioPharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares. View EIGR analyst ratings or view top-rated stocks .

What is Eiger BioPharmaceuticals' stock price target for 2024?

2 brokers have issued 12-month target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $120.00 in the next year. View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts .

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 29,800 shares, a drop of 11.3% from the March 15th total of 33,600 shares. Based on an average trading volume of 107,800 shares, the short-interest ratio is presently 0.3 days. Approximately 2.3% of the company's shares are sold short. View Eiger BioPharmaceuticals' Short Interest .

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EIGR earnings forecast .

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period in the prior year, the firm earned ($15.60) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock?

Simplify Propel Opportunities ETF holds 90,000 shares of EIGR stock, representing 0.18% of its portfolio.

When did Eiger BioPharmaceuticals' stock split?

Shares of Eiger BioPharmaceuticals reverse split before market open on Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN) , Gilead Sciences (GILD) , Skyworks Solutions (SWKS) , ZIOPHARM Oncology (ZIOP) , Amarin (AMRN) , Celldex Therapeutics (CLDX) , Catalyst Pharmaceuticals (CPRX) , Exelixis (EXEL) , SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO) .

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free EIGR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $1.30
▼
$7.17
52-Week Range: N/A

Volume: 137,800 shs
Average Volume: 103,866 shs
Market Capitalization: $2.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $120.00

Get Eiger BioPharmaceuticals alerts:

Eiger BioPharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: ∞ Upside
$120.00 Price Target
Short Interest: Healthy
2.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.83 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Eiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Eiger BioPharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.27% of the float of Eiger BioPharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Eiger BioPharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eiger BioPharmaceuticals has recently decreased by 11.31%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Eiger BioPharmaceuticals does not currently pay a dividend.
Dividend Growth
Eiger BioPharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eiger BioPharmaceuticals has received a 61.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Lonafarnib" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Eiger BioPharmaceuticals is -1.65.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Eiger BioPharmaceuticals this week, compared to 1 article on an average week.
Search Interest
6 people have searched for EIGR on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Eiger BioPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eiger BioPharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.22% of the stock of Eiger BioPharmaceuticals is held by insiders.
Percentage Held by Institutions
62.46% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

EIGR Stock News Headlines

April 16, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

April 8, 2024 | wsj.com

Requiem for Eiger Biopharmaceuticals

April 19, 2024 | Banyan Hill Publishing (Ad)

Is AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)

Rare Chance to Be an Early Investor in AI Energy Breakthrough Technology expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors.

April 2, 2024 | bizjournals.com

Peninsula biotech files for Chapter 11 bankruptcy protection

April 1, 2024 | wsj.com

Eiger BioPharmaceuticals Files for Bankruptcy

April 1, 2024 | marketwatch.com

Healthcare stocks fade as obesity-drug optimism fades

April 1, 2024 | msn.com

Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives

April 1, 2024 | finance.yahoo.com

Eiger Biopharmaceuticals Files for Chapter 11 Bankruptcy

April 19, 2024 | Banyan Hill Publishing (Ad)

Is AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)

April 1, 2024 | msn.com

Eiger reportedly files for Chapter 11, stock plunges 52%

April 1, 2024 | globenewswire.com

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

March 20, 2024 | seekingalpha.com

EIGR Eiger BioPharmaceuticals, Inc.

February 8, 2024 | bizjournals.com

New Natomas industrial property owner Eiger Capital could be buying more local assets

February 4, 2024 | bizjournals.com

Panattoni sells part of Natomas Advanced Logistics Center to Eiger Capital

January 18, 2024 | finance.yahoo.com

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

January 4, 2024 | msn.com

Eiger BioPharmaceuticals announces 1-for-30 reverse stock split

January 4, 2024 | finance.yahoo.com

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

December 7, 2023 | yahoo.com

‘Bob Eiger’ Trends on X After Elon Musk Blasts the Disney CEO With Multi-Tweet Typo

December 4, 2023 | finance.yahoo.com

Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase

November 11, 2023 | finanznachrichten.de

Eiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

September 15, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Ocular Therapeutix (OCUL), Eiger Biopharmaceuticals (EIGR)

September 13, 2023 | marketwatch.com

Eiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D Study

September 13, 2023 | markets.businessinsider.com

Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket

September 13, 2023 | msn.com

Why Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today?

September 13, 2023 | investorplace.com

Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

September 13, 2023 | reuters.com

Eiger to discontinue late-stage hepatitis drug study over safety concerns

September 12, 2023 | news.yahoo.com

Eiger to discontinue hepatitis drug study over safety concerns

See More Headlines

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:EIGR
CUSIP: N/A
CIK: 1305253
Web: www.eigerbio.com
Phone: (650) 272-6138
Fax: 650-618-1621
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $120.00
High Stock Price Target: $150.00
Low Stock Price Target: $90.00
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($59.1592)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,780,000.00
Net Margins: -590.80%
Pretax Margin: -590.79%
Return on Equity: -332.49%
Return on Assets: -99.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.24

Sales & Book Value

Annual Sales: $15.77 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $37.68 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,480,000
Free Float: 1,419,000
Market Cap: $2.55 million
Optionable: Optionable
Beta: 1.83

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. David Apelian M.B.A. (Age 59)
M.D., Ph.D., CEO & Director
Comp: $204.39k
Dr. Jeffrey S. Glenn M.D. (Age 61)
Ph.D., Scientific Founder & Independent Director
Comp: $67k
Mr. William G. Kaichoff CPA (Age 58)
CFO and Principal Financial & Accounting Officer
Mr. Christopher A. Kurtz (Age 57)
Chief Technical Officer
Mr. James Vollins J.D. (Age 55)
General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Colin Hislop M.D. (Age 66)
MBBS, Senior Vice President of Clinical & Development Operations
Dr. Colleen Craig M.D.
Senior Vice President of Metabolic Diseases

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EIGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings or view top-rated stocks.
What is Eiger BioPharmaceuticals' stock price target for 2024?: 2 brokers have issued 12-month target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $120.00 in the next year.
View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts.
Are investors shorting Eiger BioPharmaceuticals?: Eiger BioPharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 29,800 shares, a drop of 11.3% from the March 15th total of 33,600 shares. Based on an average trading volume of 107,800 shares, the short-interest ratio is presently 0.3 days. Approximately 2.3% of the company's shares are sold short.
View Eiger BioPharmaceuticals' Short Interest.
When is Eiger BioPharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EIGR earnings forecast.
How were Eiger BioPharmaceuticals' earnings last quarter?: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period in the prior year, the firm earned ($15.60) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock?: Simplify Propel Opportunities ETF holds 90,000 shares of EIGR stock, representing 0.18% of its portfolio.
When did Eiger BioPharmaceuticals' stock split?: Shares of Eiger BioPharmaceuticals reverse split before market open on Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Eiger BioPharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).
How do I buy shares of Eiger BioPharmaceuticals?: Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EIGR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial